Thymosin Alpha-1 Plus Interferon for Chronic Hepatitis C: A Clinical Trial
Combination thymosin alpha-1 and lymphoblastoid interferon for chronic hepatitis C showed potential for improved treatment response over single-drug therapy.
Quick Facts
What This Study Found
Combination thymosin alpha-1 (1 mg twice weekly) and lymphoblastoid interferon was tested as a strategy to improve sustained response rates in chronic hepatitis C over interferon monotherapy.
Key Numbers
How They Did This
Randomized clinical trial assessing one year of combination thymosin alpha-1 and lymphoblastoid interferon treatment in patients with chronic hepatitis C.
Why This Research Matters
Before direct-acting antivirals, hepatitis C treatment had very low cure rates. Thymosin alpha-1 combination therapy represented an attempt to boost immune-mediated viral clearance.
The Bigger Picture
While direct-acting antivirals have since revolutionized hepatitis C treatment, thymosin alpha-1 combination studies demonstrated the peptide's potential as an immune adjuvant in antiviral therapy.
What This Study Doesn't Tell Us
Abstract doesn't detail response rates, sample size, or comparative arm design. Pre-direct-acting-antiviral era study may have limited current clinical relevance for HCV specifically.
Questions This Raises
- ?Does thymosin alpha-1 combination therapy improve sustained viral response compared to interferon alone?
- ?Could thymosin alpha-1's immune-boosting properties benefit modern HCV or other antiviral treatments?
Trust & Context
- Key Stat:
- 1-year combination trial Thymosin alpha-1 at 1 mg twice weekly combined with interferon for a full year in chronic hepatitis C patients
- Evidence Grade:
- Moderate evidence from an RCT. Systematic clinical trial design, but outcome details not available in abstract excerpt.
- Study Age:
- Published in 1996, before direct-acting antivirals transformed hepatitis C treatment. Thymosin alpha-1's immune-boosting role remains relevant in other contexts.
- Original Title:
- Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.
- Published In:
- Gut, 39(5), 679-83 (1996)
- Authors:
- Rasi, G(3), DiVirgilio, D, Mutchnick, M G(5), Colella, F, Sinibaldi-Vallebona, P, Pierimarchi, P, Valli, B, Garaci, E
- Database ID:
- RPEP-00381
Evidence Hierarchy
Frequently Asked Questions
What is thymosin alpha-1?
Thymosin alpha-1 is a naturally occurring peptide from the thymus gland that enhances immune function, particularly T-cell activity. It's been approved in some countries as an immune modulator for viral hepatitis and as an adjunct to cancer immunotherapy.
Why combine thymosin alpha-1 with interferon?
Interferon alone had very low cure rates for hepatitis C (around 10-20% sustained response). Adding thymosin alpha-1 aimed to boost the immune system's ability to clear the virus, potentially improving cure rates through dual immune activation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00381APA
Rasi, G; DiVirgilio, D; Mutchnick, M G; Colella, F; Sinibaldi-Vallebona, P; Pierimarchi, P; Valli, B; Garaci, E. (1996). Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.. Gut, 39(5), 679-83.
MLA
Rasi, G, et al. "Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.." Gut, 1996.
RethinkPeptides
RethinkPeptides Research Database. "Combination thymosin alpha 1 and lymphoblastoid interferon t..." RPEP-00381. Retrieved from https://rethinkpeptides.com/research/rasi-1996-combination-thymosin-alpha-1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.